{"id":"W4379979709","doi":"10.1002/hon.3164_421","title":"A phase II, open‐label, multicenter study of capivasertib, a potent, oral pan‐AKT inhibitor, in patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma (CAPITAL)","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Victoria","funders":"","keywords":"Medicine; Mantle cell lymphoma; Internal medicine; Follicular lymphoma; Gastroenterology; Lymphoma; Phases of clinical research; Marginal zone B-cell lymphoma; Oncology; Clinical trial; Immunology; B cell; Marginal zone","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007526882,0.0004293838,0.001725342,0.0004441842,0.0001331957,0.00002279895,0.0006063661,0.0005180453,0.000326494],"category_scores_gemma":[0.0007939916,0.0002686285,0.00008088095,0.001227183,0.0003656193,0.0001848947,0.001189879,0.0004996755,0.000186873],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.005217772,"about_ca_system_score_gemma":0.004157921,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001022622,"about_ca_topic_score_gemma":0.000775695,"domain_scores_codex":[0.9954572,0.0005226826,0.001189136,0.0009740043,0.0008368975,0.001020118],"domain_scores_gemma":[0.9972999,0.0007751361,0.0003832319,0.0008322914,0.0003159229,0.0003935234],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"nonrandomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1974584,0.5212998,0.1617862,0.001330208,0.0007980735,0.04393779,0.0146574,0.00002137432,0.006174878,0.00007248274,0.01561028,0.03685319],"study_design_scores_gemma":[0.7287088,0.2215531,0.03570343,0.0004080335,0.0002455184,0.000196538,0.005637924,0.002568758,0.002695527,0.00003784777,0.001667382,0.0005771581],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9942682,0.00004913232,0.000004551957,0.0002639465,0.0001727357,0.004374293,0.0000191709,0.0001091822,0.0007388074],"genre_scores_gemma":[0.9975017,0.00003045194,0.0005966023,0.000366671,0.00003429229,0.0004561882,0.0000938793,0.00006193215,0.0008582575],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5312504,"threshold_uncertainty_score":0.9999766,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06263963328599681,"score_gpt":0.3822856415088418,"score_spread":0.3196460082228449,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}